Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma By Ogkologos - January 21, 2025 666 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a substudy 02C of the KEYMAKER-U02 trial Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR COVID-19 Vaccine: Distribution and Administration January 25, 2021 Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole... September 24, 2021 Rapid Genetic Test Could Help Guide Brain Cancer Surgery May 8, 2025 Could A Form of Cell Death Enhance Cancer Immunotherapy? July 29, 2019 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate Improving research with registered reports Self Destruction ¿Qué son los biosimilares para el tratamiento del cáncer?
